Penumbra, Inc. (NYSE:PEN) Stake Lifted by Barclays PLC

Barclays PLC boosted its holdings in shares of Penumbra, Inc. (NYSE:PEN - Free Report) by 65.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 29,796 shares of the company's stock after acquiring an additional 11,771 shares during the period. Barclays PLC owned about 0.08% of Penumbra worth $7,076,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in PEN. Sanctuary Advisors LLC acquired a new position in Penumbra during the third quarter worth about $367,000. Wilmington Savings Fund Society FSB acquired a new position in Penumbra during the third quarter worth about $6,995,000. Tidal Investments LLC raised its position in Penumbra by 2.7% during the third quarter. Tidal Investments LLC now owns 5,008 shares of the company's stock worth $973,000 after acquiring an additional 130 shares during the last quarter. Franklin Resources Inc. raised its position in Penumbra by 8.2% during the third quarter. Franklin Resources Inc. now owns 319,232 shares of the company's stock worth $67,473,000 after acquiring an additional 24,091 shares during the last quarter. Finally, GAMMA Investing LLC raised its position in shares of Penumbra by 160.8% in the fourth quarter. GAMMA Investing LLC now owns 446 shares of the company's stock valued at $106,000 after buying an additional 275 shares during the last quarter. Institutional investors and hedge funds own 88.88% of the company's stock.

Penumbra Stock Down 1.5 %

Shares of Penumbra stock traded down $4.55 during trading hours on Wednesday, hitting $292.36. 520,775 shares of the company's stock traded hands, compared to its average volume of 426,570. The company has a quick ratio of 3.25, a current ratio of 6.01 and a debt-to-equity ratio of 0.02. Penumbra, Inc. has a twelve month low of $148.00 and a twelve month high of $310.00. The stock has a 50 day simple moving average of $276.75 and a 200-day simple moving average of $256.41. The company has a market cap of $11.32 billion, a PE ratio of 859.88, a PEG ratio of 2.83 and a beta of 0.56.

Penumbra (NYSE:PEN - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The company reported $0.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.66 by $0.17. The company had revenue of $324.14 million for the quarter, compared to the consensus estimate of $315.72 million. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. Penumbra's revenue for the quarter was up 16.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.41 EPS. Equities research analysts anticipate that Penumbra, Inc. will post 3.67 earnings per share for the current fiscal year.

Insider Buying and Selling at Penumbra

In other news, EVP Johanna Roberts sold 600 shares of Penumbra stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $287.43, for a total value of $172,458.00. Following the completion of the transaction, the executive vice president now owns 66,539 shares in the company, valued at approximately $19,125,304.77. This trade represents a 0.89 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Arani Bose sold 12,000 shares of the company's stock in a transaction that occurred on Friday, April 25th. The shares were sold at an average price of $298.73, for a total value of $3,584,760.00. Following the sale, the director now directly owns 302,819 shares in the company, valued at approximately $90,461,119.87. This represents a 3.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 140,446 shares of company stock worth $39,543,953 in the last ninety days. 5.00% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on PEN. UBS Group reissued a "buy" rating and issued a $330.00 price objective (up previously from $320.00) on shares of Penumbra in a research report on Thursday, April 24th. Piper Sandler reissued an "overweight" rating and issued a $330.00 price objective (up previously from $250.00) on shares of Penumbra in a research report on Wednesday, February 19th. JPMorgan Chase & Co. upped their price target on shares of Penumbra from $230.00 to $285.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 19th. BTIG Research reaffirmed a "buy" rating on shares of Penumbra in a research report on Thursday, April 24th. Finally, Robert W. Baird upped their price target on shares of Penumbra from $316.00 to $325.00 and gave the stock an "outperform" rating in a research report on Thursday, April 24th. Three research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $302.40.

Penumbra Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.